Scientist, Nanotechnology

OPPORTUNITY
Mammoth is seeking a talented Scientist with demonstrated expertise in non-viral nucleic acid delivery systems for in vivo genome editing and gene therapy. The ideal candidate will have direct hands-on experience in developing, formulating and characterizing lipid nanoparticles for CRISPR genome editing. Candidates must be able to work independently and comfortable collaborating with others in multidisciplinary teams.
KEY RESPONSIBILITIES

• Initiate, direct, and perform experiments to develop and optimize non-viral delivery methodologies using lipid nanoparticle (LNP) and/or other nanoformulations for novel CRISPR systems
• Develop and execute assays assessing and characterizing LNP and novel nanoparticle formulations
• Manage direct reports and collaborate with cross-functional teams and external partners
• Record, document, analyze and present scientific data to senior staff and team members and participate in the writing of SOPs, reports, and manuscripts for external scientific communications

REQUIRED QUALIFICATIONS

• PhD in Bioengineering, chemical engineering, Material Science, Chemistry, Biophysics, biochemistry or related field with 3+ years of relevant experience
• Demonstrated hands-on experience in lipid nanoparticle formulation development for nucleic acid delivery, analytical methods for LNP characterization, tissue culture, and molecular biology

PREFERRED QUALIFICATIONS

• Hands-on experience with RNA therapeutics and chemical modifications of RNA
• Knowledge of drug delivery systems for gene therapy, lipid/polymer biophysics, and CMC concepts.
• Experience with genome editing technologies and LNP in vivo delivery
• Strong communication, presentation and data analysis skills

BENEFITS

• Company-paid health/vision/dental benefits
• Unlimited vacation and generous sick time
• Company-sponsored meals and snacks
• Wellness, caregiver and ergonomics benefits
• 401(k) with company matching

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.